Acutaas Chemicals Shares Rise on Strong Q2 Results and Upgraded FY27 Guidance
Acutaas Chemicals shares rose over 13% following a 43% year-on-year revenue increase and an 86% rise in EBITDA for the September quarter. The company raised its FY27 revenue growth guidance to around 30% and EBITDA margin guidance to 38-40%, citing strong order visibility and growth in pharmaceutical intermediates and CDMO operations. Specialty chemicals revenue declined due to product phase-out, while commodity chemicals revenue fell amid planned withdrawal. Analysts remain positive, valuing the stock with a 'Buy' rating based on sustained growth prospects.
First-hand measurement across 4 sources
We measured how 4 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (76/100). Lens Score 36/100.
Outlets measured: moneycontrol, mint, businessstandard, freepressjournal. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (75–78/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
freepressjournal broke this story on 27 Oct, 07:43 am. Other outlets followed.